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Asthma is a common condition with a well-described
pathology and consequent treatment principles. Some therapies
are very effective in controlling not only symptoms of the
disease but also the disease itself, and yet in children treatment
of this condition remains contentious.
Asthma is defined by the ational Heart, Lung and Blood
Institute as 'a chronic inflammatory disorder of airways, in
which many cells play a part, including mast cells and
eosinophils in susceptible individuals. This causes symptoms
which are usually widespread but variable, airflow obstruction
that is often, but not always, reversible spontaneously or with
treatment, and causes an associated increase in airway
responsiveness to a variety of stimuli'.' The implication of this
definition and most others is that asthma is an inflammatory
disorder. This holds true for all forms of the disease, even when
it is mild. Hence the most important treatment should be
directed at inflammation2 and the most effective anti-
inflammatory agent is the corticosteroid,' both in adults and in
children.
For many years oral corticosteroids controlled asthma very
effectively but at huge cost in terms of unwanted side-effects.
The introduction of inhaled corticosteroids (ICS) provided a
safer alternative to oral steroids; and their use has been shown
to reduce the need for systemic steroids. ICS are successful in
decreasing nonspecific bronchial hyperresponsiveness.'"
sufficiently to control asthma symptoms over a period of time.
Despite this apparent answer to the problem of asthma,
many practitioners are reluctant to use ICS in children because
of so-called 'adverse effects'. Drug effects, however, include
both adverse (or undesired) effects and beneficial effects, and in
addressing the role of ICS in the management of childhood
asthma, some clarity is required on the balance between these
two extremes.
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At the outset it should be stated that measurable systemic
effects are not equivalent to clinically relevant systemic side-
effects. Simple detection of the drug in the blood or a measured
change in a physiological variable does not necessarily denote
an adverse event. In addition measurable systemic activity is
dependent on the sensitivity of the method used. Few true
studies have looked at the clinical relevance of adverse events,
and most opponents of res have lumped all systemic activity
under adverse events.
The systemic effect of rcs depends on the amount of drug
systemically absorbed from both the gastro-intestinal tract
(GIT) and the intrapulmonary airway. Factors influencing
systemic activity include the amount swallowed (roughly 80%
of a metered dose), the affinity of the drug for receptors, and
especially selectivity for the glucocorticoid receptors,
metabolism in the circulation and liver (oral bio-availability),
activity of metabolites and systemic clearance. The fraction that
is absorbed in the pulmonary circulation is also systemically
active.
A number of strategies have been employed to minimise the
systemic activity of ICS. These include reducing the amount
swallowed, through manipulating the inhaler technique, or by
using a spacer, or by mouth washing after use. The intrinsic
structure of the ICS can be altered to increase receptor affinity,
increase glucocorticoid receptor affinity, increase first-pass
metabolism, reduce activity of metabolites and increase
systemic clearance. These manouvres have been employed with
the newer generation ICS. Spacer devices (Fig. 1) should be
considered an integral part of rcs therapy in children, and the
spacer used should be that recommended by the manufacturer
for the particular drug, as mixing and matching delivers
inconsistent dosages.
Fig. 1. Child using an inhaled steroid via a Babyhaler spacer.
It has largely been in children that adverse effects have been
of concern to practitioners treating asthma, with growth the
important variable. Surrogate markers for the systemic effects
of rcs have included measures of hypothalamopituitary axis
(HPA) activity, biochemical markers of bone mineralisation,
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short-term growth, and of course growth over time. The degree
of HPA axis suppression is dependent on a number of
variables, including dose of lCS, duration of action, frequency
of administration, time of day administered and route of
administra tion.
A number of tests have been employed to 'measure' the
systemic effect of ICS. These include both basal adrenal activity
and the more sen:sitive stimulation tests. When interpreting
such tests it must be remembered that normal cortisol secretion
varies during the course of the day, that laboratory studies may
not reflect physiological changes, that many tests are difficult
to perform, and that often changes noted are within the normal
range for a particular test.
With regard to the effect of ICS on the HPA axis, conflicting
results' reported may be due to uncontrolled studies, previous
use of oral steroids, variable duration of treatment, variable
inhaler systems and different measuring methods. Some of
these studies indicated that significant effects on basal adrenal
function (cortisol secretion) can be detected at doses of ICS
around 400 pg per day. However, no clinically reievant
endocrine effects have been reported in children who have
received such therapy for many years.
The mechanism of the effect of rcs on growth is not fully
lmderstood, but may involve both an indirect effect on growth
hormone secretion, and a direct effect on bone metabolism.
Important considerations in this regard are that the rate of
growth in childhood and final height are determined by the
impact of a range of environmental factors on genetic potential.
In addition growth measurement is subject to error, especiaJJy
when growth velocity is low (mid-childhood), where error in
3-monthJy intervals may be as high as 50%. Compounding
variables for height determination are seasonal changes, year-
by-year changes, time of onset of puberty, effect of asthma
(many asthmatic children have a slower growth rate than
normal children and a physiological delay in puberty which
does not affect final adult height), severity of asthma,' and
lastly the effect of oral steroid use.
Although short-term growth studies, usually involving
knemometry, report variable rates of lower limb growth with
ICS, long-term follow-up studies have been few. Three such
studies found no long-term effect (up to 6 years) on growth
with variables doses of rcs (up to 1100 pg/m'/d).6 In
conclusion, it appears that knemometry (short-term) studies
show effects of lCS on growth (of the lower leg) at doses from
400 pg/d, that long-term statural growth is not affected at this
or higher doses, and that knemometry may be oversensitive for
measurement of this sort.7
The use of bone turnover to reflect systemic adverse events is
based on the understanding that systemic glucocorticoid
therapy has a deleterious effect on the skeleton, leading to
decreased bone mass and ultimately to osteoporotic fractures·
Thirty to fifty per cent of patients receiving long-term (over
years) treatment with doses of prednisone of 7.5 -10 mg per
day would develop skeletal fractures.'"
Numerous methods are available for assessing bone
turnover, both biochemical and radiological. Bone densitometry
is the latest and probably the most practical, but like the other
tests described, it is associated with a number of problems.
Bone metabolism (like asthma itself) is influenced by disease
states, activity, diet and the confounding effect of oral steroids.
Although short-term studies in general have found ICS to
have no effect on systemic measures of bone metabolism,n.n it
is the long-term effects that would be more important. Few
studies have been performed in children, but in one sentinel
study Agertoft and Pedersen13 found no change in bone density
in children after 4.5 years (mean dose of rcs 691 pg/d)
compared with steroid-naIve asthmatics.
In conclusion, while there is no indication of increased risk of
osteoporosis or fractures in children on ICS, it is wise to aim for
the lowest dose with long-term treatment. However, at the
onset of treatment of asthma use of high-dose rcs is becoming
a popular way of gaining initial control of the disease.
BENEFICIAL EFFECTS OF ICS
It has become common practice to discuss adverse events due
to lCS as the sole marlifestation of drug activity. This is not the
case. Many beneficial systemic effects are known or becoming
obvious.
As has been discussed, uncontrolled asthma can cause poor
growth in childhood and delayed puberty, and this effect is
magnified by the need for repeated courses of oral steroids.
There is evidence that growth is improved with ICS. Short-term
growth was marginally better in a fluticasone propionate-
treated group than in a placebo control group (N = 13) (not
statistically significant)," and this probably reflects an overall
improvement in health.
Three studies comparing asthmatic patients given ICS early
with patients in whom the introduction of lCS was delayed
demonstrated increasing loss of lung function with increasing
delay in introduction of lCS.";'17 This would impact on cost and
number of exacerbations, and could have future medicolegal
implications.
An exacerbation of asthma, especially a severe exacerbation,
is a serious illness. There is evidence that treatment with ICS
(fluticasone propionate) results in fewer exacerbations than
treatment with sodium cromoglycate17 and has a Significantly
greater effect than treatment with ~-agonists,'6and together
with the benefits of improved long-term control and quality of
life, the cost of rcs is lower than that of some other agents,
such as sodium cromoglycate. m:D
·CO CLUSION
Concerns about the systemic unwanted effects of ICS have
greatly limited their use, especiaJJy in children. The adverse
effects of inhaled glucocorticosteroids are dose-related, with
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little or no evidence of clinically relevant systemic unwanted
effects at doses of < -lOO J.Ig/ d. In most patients optimal asthma
control can be maintained with these or lower doses. There are
currently no anti-inflammatory drugs that are as effective as
inhaled glucocorticosteroids in the first-line treatment of
asthma.
In children with asthma it is reassuring to note that
guidelines for management now advocate the use of ICS in all
severities of persistent disease" (and not just for severe
asthma), and that with the newer inhaled corticosteroids and
delivery devices (fluticasone propionate or budesonide
turbuhaler) equal effect may be achieved at half the dose of
both BDP and budesonide in a metered dose inhaler1Y.20
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DRUG ALERT
ROCHE WITHDRAWS POSICOR
Roche announced on Monday 8 June 1998 the voluntary
withdrawal of the antihypertensive and anti-anginal
medication, Posicor (mibefradil), and is advising
physicians to propose alternative therapies to their
patients.
This action is based on evolving information
concerning the potential for drug interaction, some of
them serious, which may occur when Posicor is taken
together with some other medications. The decision
follows analysis of the preliminary results of a 3-year
long-term study of Posicor in congestive heart failure-
this demonstrated no significant difference beh-veen
Posicor and placebo when added to standard therapy in
this patient population, but did provide further
information on drug interaction .
. In both hypertension and chronic angina pectoris,
Posicor has proved to be consistently effective and well
tolerated when used appropriately. However, the
combination of Posicor and some other commonly used
drugs, among them cardiovascular agents, may increase
the frequency of the side-effects of these other
medications.
In principle, drug interactions can be addressed by
appropriate labelling; however, in the case of Posicor,
Roche believes that the complexity of such prescribing
information would make it too difficult to implement.
As patient well-being is of the highest priority to Roche,
the company has preferred to voluntarily withdraw the
compound from all markets.
The company is working closely with regulatory
authorities to appropriately inform physicians and other
health care professionals of its decision.
Patients hould not simply discontinue treatment with
Posicor; instead they should promptly consult their
physicians about appropriate alternative therapy. In
addition, patients should not add any new medication
to their present treatment without consulting their
physicians.
Enquiries: Kelvyn Henry, Public Affairs Director, te!
(011) 928- 73-1 or (011) 974-5335.
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